Goldan Keith A. 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Goldan Keith A.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-02-10$15.50/sh−3,777$58,559→ 90,746 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.